Trastuzumab duocarmazine by Byondis for Gastric Cancer: Likelihood of Approval

Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Gastric Cancer.

In less-studied female mice, scientists find hormone that could lead to new bone disease treatments

Scientists have discovered a hormone responsible for keeping bones sturdy in lactating people and mice, which could have broad applications for treating bone conditions like

July 11, 2024

Cue Health’s Covid-19 tests could give false results, FDA warns

The Food and Drug Administration warned consumers Monday to not use Cue Health’s at-home Covid-19 tests. This follows an FDA warning letter to the company

May 13, 2024

Malaysia approves Antengene’s XPOVIO for multiple myeloma

The drug’s introduction in Malaysia is anticipated to bring new therapeutic options to the clinical management of MM. Credit: Pickadook/Shutterstock. Antengene has received approval from

August 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.